Most Read Articles
Dr. Joseph Delano Fule Robles, 5 days ago

A recent study conducted by The University of Hong Kong (HKU) revealed that long-term use of proton pump inhibitors (PPIs) is associated with a significantly increased risk of gastric cancer even in patients who have had Helicobacter pylori eradicated. 

5 days ago
The 5-year survival rates for human papillomavirus (HPV)-associated cancers vary greatly according to age and race, with Caucasians and younger patients tending to have better survival, according to a recent US study.
6 days ago
High levels of marijuana exposure appear to not be longitudinally associated with prevalent albuminuria and substantial changes in estimated glomerular filtration rate by cystatin C (eGFRcys), a recent US epidemiological study has shown.
4 days ago
Men with breast cancer have tumours that are typically of the human epidermal growth factor receptor 2-negative Luminal B subtype and positive for oestrogen receptor, progesterone receptor and androgen receptor, according to the results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program study.

BP-BES better than DP-DES at reducing adverse events, stent thrombosis

5 days ago

BP-BES (biodegradable polymer biolimus-eluting stents) leads to lower rates of target lesion revascularization (TLR), major adverse cardiac events (MACE) and stent thrombosis (ST) at 5 years compared with DP-DES (durable polymer drug-eluting stents), according to a new meta-analysis.

After applying the selection criteria, the meta-analysis was performed on five studies corresponding to 4,687 patients. The studies were retrieved from the databases of the Cochrane Library, Embase and PubMed.

Pooled data from four trials showed that BP-BES significantly reduced the risk of MACE compared to first-generation DP-DES (odds ratio [OR], 0.80; 95 percent CI, 0.68 to 0.95; p=0.01). In contrast, the risk of MACE was not significantly different between BP-BES and second-generation DP-DES (OR, 0.96; 0.68 to 1.37p =0.38).

Overall, however, BP-BES significantly reduced the risk of MACE compared with DP-DES (OR, 0.83; 0.71 to 0.97; p=0.02). Similarly, BP-BES significantly reduced the risk of TLR compared to first-generation (OR, 0.73; 0.58 to 0.92; p=0.008) but not second-generation (OR, 1.34; 0.63 to 2.83; p=0.44) DP-DES. Overall, BP-BES was better than DP-DES in reducing the risk of TLR (OR, 0.77; 0.62 to 0.96; p=0.02).

BP-BES was again superior to first-generation (OR, 0.57; 0.39 to 0.82; p=0.002) but not second-generation (OR, 87; 0.35 to 2.16; p=0.76) DP-DES in reducing the risk of ST. Overall, the risk of ST was significantly lower with BP-BES than DP-DES (OR, 0.60; 0.43 to 0.84; p=0.003).

On the other hand, BP-BES showed no clear advantage over DP-DES in reducing the risk of death (OR, 0.89; 0.72 to 1.11; p=0.30), myocardial infarctions (OR, 0.88; 0.70 to 1.10; p=0.27) and target vessel revascularization (OR, 0.89; 0.73 to 1.08; p=0.23).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 5 days ago

A recent study conducted by The University of Hong Kong (HKU) revealed that long-term use of proton pump inhibitors (PPIs) is associated with a significantly increased risk of gastric cancer even in patients who have had Helicobacter pylori eradicated. 

5 days ago
The 5-year survival rates for human papillomavirus (HPV)-associated cancers vary greatly according to age and race, with Caucasians and younger patients tending to have better survival, according to a recent US study.
6 days ago
High levels of marijuana exposure appear to not be longitudinally associated with prevalent albuminuria and substantial changes in estimated glomerular filtration rate by cystatin C (eGFRcys), a recent US epidemiological study has shown.
4 days ago
Men with breast cancer have tumours that are typically of the human epidermal growth factor receptor 2-negative Luminal B subtype and positive for oestrogen receptor, progesterone receptor and androgen receptor, according to the results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program study.